Conference Coverage

Inotuzumab continues to wow against relapsed/refractory ALL

Publish date: June 12, 2016

 

At THE EHA CONGRESS

References

The study was funded by Pfizer. Dr. Kantarjian disclosed research support from the company. Dr. Izraeli reported having no relevant disclosures.

Pages

Recommended Reading

CAR-T cell therapy rolls on in pediatric ALL
MDedge Family Medicine
VIDEO: Search for genetic risk factors may improve vincristine therapy
MDedge Family Medicine
Study: Pediatric cancer patients have high rate of germline mutations in predisposition genes
MDedge Family Medicine
Death from late effects of childhood cancer on decline
MDedge Family Medicine
Children’s cancer survival steadily increasing
MDedge Family Medicine
Materials help families find support for children with serious illnesses
MDedge Family Medicine
Inherited thrombocytopenia type is a risk factor for hematologic cancers
MDedge Family Medicine